8-K
filed July 28, 2026, 5:11 PM ET
ticker VYNE
CIK 0001566044
M&A
confidence high
sentiment neutral
materiality 1.00
Yarrow Bioscience completes reverse merger with VYNE; Yarrow stockholders own 97% of combined company
VYNE Therapeutics Inc.
- VYNE valued at $8.5M, Pre-Merger Yarrow at $272.9M; exchange ratio 0.7171 shares of new co per Yarrow share.
- Pre-Merger Yarrow stockholders own ~97% of combined company; VYNE stockholders ~3%.
- VYNE paid $17.3M cash dividend ($0.40242/share) to its stockholders prior to close.
- New board and officers appointed: CEO Rebecca Frey, CFO Tyler Zeronda, and four other C-suite; board of six members.
- Pre-Merger Yarrow raised $200M in total: $100M Series A preferred and $100M PIPE pre-closing.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rebecca Frey was appointed as Chief Executive Officer at VYNE Therapeutics Inc..
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Steven Ryder was appointed as Chief Medical Officer at VYNE Therapeutics Inc..
- Action
- appointed
- Role
- Chief Medical Officer
Exact text from the filing
the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Domzalski resigned as President and Chief Executive Officer at VYNE Therapeutics Inc..
- Action
- resigned
- Role
- President and Chief Executive Officer
Exact text from the filing
each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mutya Harsch resigned as Chief Legal Officer and General Counsel at VYNE Therapeutics Inc..
- Action
- resigned
- Role
- Chief Legal Officer and General Counsel
Exact text from the filing
each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Iain Stuart resigned as Chief Scientific Officer at VYNE Therapeutics Inc..
- Action
- resigned
- Role
- Chief Scientific Officer
Exact text from the filing
each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tyler Zeronda was appointed as Chief Financial Officer at VYNE Therapeutics Inc..
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rachael Alford was appointed as Chief Operating Officer at VYNE Therapeutics Inc..
- Action
- appointed
- Role
- Chief Operating Officer
Exact text from the filing
the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer and Rachael Alford, Ph.D. as the Company's Chief Operating Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Lori Payton was appointed as Chief Development Officer at VYNE Therapeutics Inc..
- Action
- appointed
- Role
- Chief Development Officer
Exact text from the filing
the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.